Overview
Australian clinical-stage biopharmaceutical company developing MDMA, psilocybin, and cannabis-derived therapeutics for mental health conditions with a data-driven clinical trial platform. They operate licensed clinics to generate real-world evidence for regulatory submissions.
More in Psychedelics
Latest industry news
NIH-Backed Device Gives People With Paralysis a New Path to Communication
2026-10-14 ยท Research
ABILITY Neurotech Begins Clinical Testing of Its Brain-Computer Interface System
2026-10-13 ยท Research
Flourish Emerges From Stealth With Bezos and Google Ventures Backing to Decode the Nervous System
2026-10-12 ยท Funding
Cala Health Launches Next-Generation TAPS Therapy Wearable Nationwide for Tremor and Parkinson's Patients
2026-10-11 ยท Product
Company details
Category
๐ Psychedelics
Location
Perth, Australia
Funding
Public ยท ASX
Website
emyria.com.auListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages โ